triclabendazole (Rx)

Brand and Other Names:Egaten
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 250mg

Fascioliasis

Indicated for treatment of fascioliasis

10 mg/kg PO x2 doses administered 12 hr apart

Tablets are scored and divisible into two equal halves of 125 mg

If dosage cannot be adjusted exactly, round dose upwards

Dosage Modifications

Renal or hepatic impairment: Not studied

Dosage Forms & Strengths

tablet

  • 250mg

Fascioliasis

Indicated for treatment of fascioliasis in patients ≥6 years

<6 years: Safety and efficacy not established

≥6 years

  • 10 mg/kg PO x2 doses administered 12 hr apart
  • Tablets are scored and divisible into two equal halves of 125 mg
  • If dosage cannot be adjusted exactly, round dose upwards

Dosage Modifications

Renal or hepatic impairment: Not studied

Next:

Interactions

Interaction Checker

and triclabendazole

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (10)

              • bedaquiline

                bedaquiline and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • ceritinib

                ceritinib and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • chloroquine

                chloroquine and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • clarithromycin

                clarithromycin and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • crizotinib

                crizotinib and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • desflurane

                desflurane and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • entrectinib

                triclabendazole and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

              • fexinidazole

                fexinidazole and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

              • lefamulin

                lefamulin and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug.

              • pitolisant

                triclabendazole and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

              Monitor Closely (113)

              • albuterol

                albuterol and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • alfuzosin

                alfuzosin and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • ambrisentan

                triclabendazole will increase the level or effect of ambrisentan by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • amiodarone

                triclabendazole and amiodarone both increase QTc interval. Use Caution/Monitor.

                triclabendazole will increase the level or effect of amiodarone by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • anagrelide

                triclabendazole and anagrelide both increase QTc interval. Use Caution/Monitor.

              • apomorphine

                apomorphine and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • arformoterol

                arformoterol and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • aripiprazole

                aripiprazole and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • arsenic trioxide

                triclabendazole and arsenic trioxide both increase QTc interval. Use Caution/Monitor.

              • artemether

                triclabendazole and artemether both increase QTc interval. Use Caution/Monitor.

              • artemether/lumefantrine

                triclabendazole and artemether/lumefantrine both increase QTc interval. Use Caution/Monitor.

              • asenapine

                triclabendazole and asenapine both increase QTc interval. Use Caution/Monitor.

              • atomoxetine

                atomoxetine and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • bortezomib

                triclabendazole will increase the level or effect of bortezomib by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • carisoprodol

                triclabendazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • citalopram

                triclabendazole and citalopram both increase QTc interval. Use Caution/Monitor.

                triclabendazole will increase the level or effect of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • clobazam

                triclabendazole will increase the level or effect of clobazam by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • clofazimine

                triclabendazole and clofazimine both increase QTc interval. Use Caution/Monitor.

              • clomipramine

                triclabendazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • clozapine

                clozapine and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • dasatinib

                dasatinib and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • degarelix

                degarelix and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • deutetrabenazine

                triclabendazole and deutetrabenazine both increase QTc interval. Modify Therapy/Monitor Closely. For patients requiring deutetrabenazine doses >24 mg/day and are taking other drugs known to prolong QTc, assess the QTc interval before and after increasing the dose of deutetrabenazine or other medications known to prolong QTc.

              • dexlansoprazole

                triclabendazole will increase the level or effect of dexlansoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • diazepam

                triclabendazole will increase the level or effect of diazepam by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • diazepam intranasal

                triclabendazole will increase the level or effect of diazepam intranasal by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Strong or moderate CYP2C19 inhibitors may decrease rate of diazepam elimination, thereby increasing adverse reactions to diazepam.

              • disopyramide

                triclabendazole and disopyramide both increase QTc interval. Use Caution/Monitor.

              • dofetilide

                triclabendazole and dofetilide both increase QTc interval. Use Caution/Monitor.

              • dolasetron

                dolasetron and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • donepezil

                donepezil and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • doxepin

                doxepin and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • dronedarone

                triclabendazole and dronedarone both increase QTc interval. Use Caution/Monitor.

              • efavirenz

                efavirenz and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • eliglustat

                triclabendazole and eliglustat both increase QTc interval. Use Caution/Monitor.

              • encorafenib

                triclabendazole and encorafenib both increase QTc interval. Use Caution/Monitor.

              • escitalopram

                triclabendazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • esomeprazole

                triclabendazole will increase the level or effect of esomeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • etravirine

                triclabendazole will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • fingolimod

                fingolimod and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • flibanserin

                triclabendazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • fluoxetine

                triclabendazole and fluoxetine both increase QTc interval. Use Caution/Monitor.

              • fosphenytoin

                triclabendazole will increase the level or effect of fosphenytoin by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • fostemsavir

                triclabendazole and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

              • granisetron

                triclabendazole and granisetron both increase QTc interval. Use Caution/Monitor.

              • haloperidol

                triclabendazole and haloperidol both increase QTc interval. Use Caution/Monitor.

              • histrelin

                triclabendazole and histrelin both increase QTc interval. Use Caution/Monitor.

              • ibutilide

                triclabendazole and ibutilide both increase QTc interval. Use Caution/Monitor.

              • ifosfamide

                triclabendazole will increase the level or effect of ifosfamide by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • iloperidone

                triclabendazole and iloperidone both increase QTc interval. Use Caution/Monitor.

              • imipramine

                triclabendazole will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • indacaterol, inhaled

                triclabendazole and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor.

              • inotuzumab

                triclabendazole and inotuzumab both increase QTc interval. Use Caution/Monitor.

              • lansoprazole

                triclabendazole will increase the level or effect of lansoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • lapatinib

                triclabendazole and lapatinib both increase QTc interval. Use Caution/Monitor.

              • lenvatinib

                triclabendazole and lenvatinib both increase QTc interval. Use Caution/Monitor.

              • leuprolide

                triclabendazole and leuprolide both increase QTc interval. Use Caution/Monitor.

              • levofloxacin

                triclabendazole and levofloxacin both increase QTc interval. Use Caution/Monitor.

              • lofexidine

                triclabendazole and lofexidine both increase QTc interval. Use Caution/Monitor.

              • lopinavir

                triclabendazole and lopinavir both increase QTc interval. Use Caution/Monitor.

              • lumefantrine

                triclabendazole and lumefantrine both increase QTc interval. Use Caution/Monitor.

              • methadone

                triclabendazole and methadone both increase QTc interval. Use Caution/Monitor.

              • methsuximide

                triclabendazole will increase the level or effect of methsuximide by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • mifepristone

                triclabendazole and mifepristone both increase QTc interval. Use Caution/Monitor.

              • modafinil

                triclabendazole will increase the level or effect of modafinil by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • moxifloxacin

                triclabendazole and moxifloxacin both increase QTc interval. Use Caution/Monitor.

              • nelfinavir

                triclabendazole will increase the level or effect of nelfinavir by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • nilotinib

                triclabendazole and nilotinib both increase QTc interval. Use Caution/Monitor.

              • ofloxacin

                triclabendazole and ofloxacin both increase QTc interval. Use Caution/Monitor.

              • olanzapine

                triclabendazole and olanzapine both increase QTc interval. Use Caution/Monitor.

              • omeprazole

                triclabendazole will increase the level or effect of omeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • ondansetron

                triclabendazole and ondansetron both increase QTc interval. Use Caution/Monitor.

              • osilodrostat

                osilodrostat and triclabendazole both increase QTc interval. Use Caution/Monitor.

              • osimertinib

                triclabendazole and osimertinib both increase QTc interval. Use Caution/Monitor.

              • ospemifene

                triclabendazole will increase the level or effect of ospemifene by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • paliperidone

                triclabendazole and paliperidone both increase QTc interval. Use Caution/Monitor.

              • panobinostat

                triclabendazole and panobinostat both increase QTc interval. Use Caution/Monitor.

              • pantoprazole

                triclabendazole will increase the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • pasireotide

                triclabendazole and pasireotide both increase QTc interval. Use Caution/Monitor.

              • pazopanib

                triclabendazole and pazopanib both increase QTc interval. Use Caution/Monitor.

              • pentamidine

                triclabendazole and pentamidine both increase QTc interval. Use Caution/Monitor.

                triclabendazole will increase the level or effect of pentamidine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • phenobarbital

                triclabendazole will increase the level or effect of phenobarbital by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • phenytoin

                triclabendazole will increase the level or effect of phenytoin by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • pimavanserin

                triclabendazole and pimavanserin both increase QTc interval. Use Caution/Monitor.

              • pimozide

                triclabendazole and pimozide both increase QTc interval. Use Caution/Monitor.

              • primaquine

                triclabendazole and primaquine both increase QTc interval. Use Caution/Monitor.

              • procainamide

                triclabendazole and procainamide both increase QTc interval. Use Caution/Monitor.

              • progesterone micronized

                triclabendazole will increase the level or effect of progesterone micronized by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • propafenone

                triclabendazole and propafenone both increase QTc interval. Use Caution/Monitor.

              • quetiapine

                triclabendazole and quetiapine both increase QTc interval. Use Caution/Monitor.

              • quinidine

                triclabendazole and quinidine both increase QTc interval. Use Caution/Monitor.

              • quinine

                triclabendazole and quinine both increase QTc interval. Use Caution/Monitor.

              • rabeprazole

                triclabendazole will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • ranolazine

                triclabendazole and ranolazine both increase QTc interval. Use Caution/Monitor.

              • ribociclib

                triclabendazole and ribociclib both increase QTc interval. Use Caution/Monitor.

              • risperidone

                triclabendazole and risperidone both increase QTc interval. Use Caution/Monitor.

              • romidepsin

                triclabendazole and romidepsin both increase QTc interval. Use Caution/Monitor.

              • saquinavir

                triclabendazole and saquinavir both increase QTc interval. Use Caution/Monitor.

              • sertraline

                triclabendazole will increase the level or effect of sertraline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • sorafenib

                triclabendazole and sorafenib both increase QTc interval. Use Caution/Monitor.

              • sotalol

                triclabendazole and sotalol both increase QTc interval. Use Caution/Monitor.

              • stiripentol

                triclabendazole will increase the level or effect of stiripentol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • sunitinib

                triclabendazole and sunitinib both increase QTc interval. Use Caution/Monitor.

              • tetrabenazine

                triclabendazole and tetrabenazine both increase QTc interval. Use Caution/Monitor.

              • thioridazine

                triclabendazole and thioridazine both increase QTc interval. Use Caution/Monitor.

              • tofacitinib

                triclabendazole will increase the level or effect of tofacitinib by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • toremifene

                triclabendazole and toremifene both increase QTc interval. Use Caution/Monitor.

              • trazodone

                triclabendazole and trazodone both increase QTc interval. Use Caution/Monitor.

              • trimipramine

                triclabendazole will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • triptorelin

                triclabendazole and triptorelin both increase QTc interval. Use Caution/Monitor.

              • vandetanib

                triclabendazole and vandetanib both increase QTc interval. Use Caution/Monitor.

              • vemurafenib

                triclabendazole and vemurafenib both increase QTc interval. Use Caution/Monitor.

              • voriconazole

                triclabendazole and voriconazole both increase QTc interval. Use Caution/Monitor.

                triclabendazole will increase the level or effect of voriconazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • ziprasidone

                triclabendazole and ziprasidone both increase QTc interval. Use Caution/Monitor.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                >10%

                10 mg/kg total

                • Abdominal pain (56%)
                • Hyperhidrosis (23%)

                20 mg/kg total in 2 divided doses

                • Abdominal pain (93%)
                • Hyperhidrosis (25%)
                • Nausea (18%)
                • Decreased appetite (18%)
                • Headache (14%)
                • Urticaria (11%)

                1-10% (10 mg/kg total)

                Vertigo (9%)

                Nausea (8%)

                Urticaria (7%)

                Vomiting (6%)

                Headache (6%)

                Dyspnea (5%)

                Pruritus (4%)

                Asthenia (4%)

                Musculoskeletal chest pain (4%)

                Cough (4%)

                Decreased appetite (3%)

                Chest pain (3%)

                Pyrexia (2%)

                Jaundice (2%)

                Chest discomfort (2%)

                1-10% (20 mg/kg total in 2 divided doses)

                Vomiting (7%)

                Diarrhea (7%)

                Elevated bilirubin (6.8%)

                Elevated AST (4.5%)

                Elevated ALP (4.2%)

                Pruritus (4%)

                Musculoskeletal chest pain (4%)

                Elevated ALT (3%)

                Postmarketing Reports

                Resistance to triclabendazole reported outside the United States

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity to triclabendazole and/or to other benzimidazole derivatives or to any of the excipients

                Cautions

                Transient QT prolongation noted; monitor ECG in patients with a history of QT prolongation or when used in patients who receive drugs that prolong the QT interval

                Drug interactions overview

                • In vitro data suggest coadministration of triclabendazole and CYP2C19 substrates may increase plasma concentrations of CYP2C19 substrates; potential elevated concentrations of CYP2C19 substrates is expected to be transient based on the short elimination half-life and short treatment duration of triclabendazole
                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy

                There are no available data on use in pregnant women to inform a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

                Lactation

                There are no data on presence in human milk, effects on the breastfed infant, or effects on milk production

                Published animal data indicate that triclabendazole is detected in goat milk when administered as a single dose to one lactating animal

                When a drug is present in animal milk, it is likely that the drug will be present in human milk

                Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Mechanism of action is not fully elucidated

                Studies in vitro and/or in infected animals suggest that triclabendazole and its active metabolites (sulfoxide and sulfone) are absorbed by the tegument of the immature and mature worms of Fasciola hepatica and Fasciola gigantica, leading to a decrease of the resting membrane potential, inhibition of tubulin function as well as protein and enzyme synthesis

                Absorption

                Peak plasma concentration: 1.16 micromol/L (triclabendazole); 38.6 micromol/L (sulfoxide); 2.29 micromol/L (sulfone)

                Peak plasma time: 3-4 hr AUC: 5.72 micromol⋅hr/L (triclabendazole); 386 micromol⋅hr/L (sulfoxide); 30.5 micromol⋅hr/L (sulfone)

                Metabolism

                Primarily metabolized by CYP1A2 (~64%) into its active sulfoxide metabolite and to a lesser extent by CYP2C9, CYP2C19, CYP2D6, CYP3A, and FMO

                Sulfoxide metabolite is further metabolized primarily by CYP2C9 to the active sulfone metabolite and to a lesser extent by CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, and CYP3A4

                Elimination

                Half-life: 8 hr (triclabendazole); 14 hr (sulfoxide); 11 hr (sulfone)

                No excretion data on humans

                Excretion (in animals): Feces (90% [sulfoxide and sulfone metabolite]); urine (<10%)

                Previous
                Next:

                Administration

                Oral Administration

                Administer with food

                Swallow tablet (whole or divided in half) with water

                Alternatively, may be crushed and mixed with applesauce (stable up to 4 hr)

                Storage

                Tablets: Store in original container at <30°C (86°F)

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.